Treatment of monomorphic B-cell lymphoma with rituximab after liver transplantation in a child.
Rituximab, a monoclonal antibody directed against the B-cell specific CD20 antigen has been used with success in post-transplant lymphoproliferative disorder (PTLD) of B-cell phenotype. However, the use of such drug in children with liver transplantation and PTLD is very limited. We report a 2-yr-old liver transplant recipient with monomorphic non-Hodgkin lymphoma of B-cell origin. The lymphoma did not respond to immunosuppression withdrawal, with a subsequent allograft rejection. Despite resumption of immunosuppression and rejection treatment, the lymphoma was successfully treated with rituximab.
Bueno
Javier
J
Department of Pediatric Surgery, Complejo Hospitalario Universitario Juan Canalejo, As Xubias 84, 15006 A Coruña, Spain. jbueno@canalejo.org
Ramil
Carmen
C
Somoza
Ivan
I
Sanchez-Galindo
Amelia
A
Solar
Alfonso
A
Arnal
Francisco
F
Alvarez
Augusto
A
Sánchez-Mozo
Pilar
P
Gómez
Manuel
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D006801:Humans; D007223:Infant; D016031:Liver Transplantation; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab